### Pharmacogenomic Associations for rs121913529

The variant **rs121913529** is located in the **KRAS** gene, which is a well-known oncogene. While the TogoVar API data does not explicitly mention pharmacogenomic associations, the KRAS gene and its variants, including rs121913529, are widely studied in the context of cancer therapies, particularly in colorectal cancer, lung cancer, and pancreatic cancer. Below is a summary based on the retrieved data and external knowledge:

---

#### 1. **Variant Identification**
   - **rs Number**: [rs121913529](https://identifiers.org/dbsnp/rs121913529)
   - **Gene**: KRAS
   - **HGVS Notation**:
     - **Protein Change**: p.Gly12Val, p.Gly12Ala, p.Gly12Asp (depending on the nucleotide substitution)
     - **Transcript Change**: c.35G>T, c.35G>C, c.35G>A
   - **TogoVar Link**: [TogoVar rs121913529](https://togovar.org/variant/rs121913529)

---

#### 2. **Pharmacogenomic Relevance**
   - **KRAS Variants and Anti-EGFR Therapy**:
     - Variants in the KRAS gene, including rs121913529, are associated with resistance to anti-EGFR (epidermal growth factor receptor) therapies such as **cetuximab** and **panitumumab** in colorectal cancer.
     - Patients with activating KRAS mutations (e.g., p.Gly12Val, p.Gly12Asp) are typically excluded from receiving these therapies because the mutations lead to constitutive activation of the KRAS protein, bypassing the need for EGFR signaling.
   - **Lung Cancer and Targeted Therapy**:
     - KRAS mutations, including rs121913529, are also relevant in non-small cell lung cancer (NSCLC). They are associated with poor response to certain tyrosine kinase inhibitors (TKIs) targeting EGFR.
   - **Pancreatic Cancer**:
     - KRAS mutations are common in pancreatic cancer, and their presence can influence the choice of chemotherapy regimens.

---

#### 3. **Disease Associations**
   - The variant is associated with multiple cancers, including:
     - **Non-small cell lung carcinoma (NSCLC)**
     - **Colorectal cancer**
     - **Pancreatic cancer**
     - **Ovarian cancer**
   - These associations highlight its role in tumorigenesis and its potential as a biomarker for therapy selection.

---

#### 4. **Predictive Models**
   - **AlphaMissense**: 0.9949–0.9984 (high pathogenicity prediction)
   - **SIFT**: 0.0–0.03 (deleterious)
   - **PolyPhen**: 0.653–0.985 (probably damaging)

---

#### 5. **Allele Frequency**
   - The variant is rare in the general population:
     - **gnomAD Exomes**: Allele frequency ranges from 6.8e-07 to 2.7e-06.
     - **gnomAD Genomes**: Allele frequency is 1.3e-05.

---

#### 6. **Clinical Implications**
   - Testing for KRAS mutations, including rs121913529, is a standard practice in oncology to guide treatment decisions, particularly in colorectal and lung cancers.
   - Pharmacogenomic guidelines, such as those from the **Clinical Pharmacogenetics Implementation Consortium (CPIC)** or **National Comprehensive Cancer Network (NCCN)**, recommend KRAS genotyping before initiating anti-EGFR therapies.

---

### Sources
- [TogoVar rs121913529](https://togovar.org/variant/rs121913529)
- [dbSNP rs121913529](https://identifiers.org/dbsnp/rs121913529)
- [gnomAD Variant Data](https://gnomad.broadinstitute.org/variant/12-25245350-C-T?dataset=gnomad_r4)

---

### 日本語での説明

#### 薬理ゲノミクス関連性
**rs121913529**は、**KRAS**遺伝子に位置する変異で、特にがん治療において重要な役割を果たします。以下はその概要です：

1. **抗EGFR療法との関連性**:
   - KRAS変異（例: p.Gly12Val, p.Gly12Asp）は、**セツキシマブ**や**パニツムマブ**などの抗EGFR療法に対する耐性と関連しています。
   - 大腸がん患者でKRAS変異が確認された場合、これらの治療法は通常適用されません。

2. **肺がんと標的治療**:
   - KRAS変異は非小細胞肺がん（NSCLC）でも見られ、特定のEGFRチロシンキナーゼ阻害剤（TKI）に対する反応性が低いことが知られています。

3. **膵臓がん**:
   - KRAS変異は膵臓がんで一般的であり、化学療法の選択に影響を与える可能性があります。

#### 臨床的意義
KRAS変異の検査は、特に大腸がんや肺がんの治療選択を決定するための標準的なプロセスです。

#### 出典
- [TogoVar rs121913529](https://togovar.org/variant/rs121913529)
- [dbSNP rs121913529](https://identifiers.org/dbsnp/rs121913529)
- [gnomAD Variant Data](https://gnomad.broadinstitute.org/variant/12-25245350-C-T?dataset=gnomad_r4)